Contact
searchSearch
HMP Global
Login

HRR

Videos

Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD
Videos
Selecting PARP Inhibitors for Patients With ER-Positive Early Breast Cancer
12/12/2023
Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD
Cynthia Ma, MD, leads part 3 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting PARP inhibitors for patients with ER-positive early breast cancer.
Cynthia Ma, MD, leads part 3 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting PARP inhibitors for patients with ER-positive early breast cancer.
Cynthia Ma, MD, leads part 3 of...
12/12/2023
Oncology
Shahneen Sandhu, MBBS, Peter MacCallum Cancer Centre
Videos
Prevalence of DNA Repair Defects Among Patients With Metastatic Prostate Cancer
11/02/2023
Shahneen Sandhu, MBBS
In a prospective observational study, approximately 14% of patients with metastatic prostate cancer harbored at least 1 HRR gene alteration, most commonly BRCA.
In a prospective observational study, approximately 14% of patients with metastatic prostate cancer harbored at least 1 HRR gene alteration, most commonly BRCA.
In a prospective observational...
11/02/2023
Oncology
Elena Castro, MD, PhD Hospital Universitario 12 de Octubre
Videos
Niraparib Plus Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Alterations
11/01/2023
Elena Castro, MD, PhD
Elena Castro, MD, shares final results from the MAGNITUDE study evaluating niraparib plus abiraterone acetate plus prednisone for patients with metastatic castration-resistant prostate cancer and HRR gene alterations.
Elena Castro, MD, shares final results from the MAGNITUDE study evaluating niraparib plus abiraterone acetate plus prednisone for patients with metastatic castration-resistant prostate cancer and HRR gene alterations.
Elena Castro, MD, shares final...
11/01/2023
Oncology
Eleni Efstathiou, MD, Houston Methodist Cancer Center
Videos
Niraparib Plus Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer and HRR Alterations
02/27/2023
At 2023 ASCO Genitourinary Cancers Symposium, Eleni Efstathiou, MD, shared phase 3 data which support the use of niraparib with abiraterone acetate and prednisone among patients with metastatic castration-resistant prostate cancer and BRCA...
At 2023 ASCO Genitourinary Cancers Symposium, Eleni Efstathiou, MD, shared phase 3 data which support the use of niraparib with abiraterone acetate and prednisone among patients with metastatic castration-resistant prostate cancer and BRCA...
At 2023 ASCO Genitourinary...
02/27/2023
Oncology
Omar Nadeem, MD
Videos
Teclistamab Achieves Deep MRD-Negative Responses in High-Risk Smoldering Myeloma
06/15/2026
Omar Nadeem, MD, discusses results from the phase 2 ImmunoPRISM trial evaluating teclistamab in patients with high-risk smoldering multiple myeloma.
Omar Nadeem, MD, discusses results from the phase 2 ImmunoPRISM trial evaluating teclistamab in patients with high-risk smoldering multiple myeloma.
Omar Nadeem, MD, discusses...
06/15/2026
Oncology
Vincent Chung, MD
Videos
Pembrolizumab and Olaparib Combination Demonstrates Signals of Activity in BRCA-Mutated Pancreatic Cancer
06/12/2026
Vincent Chung, MD, disucsses results from the phase 2 SWOG S2001 trial which demonstrated that olaparib plus pembrolizumab improved response and progression-free survival in germline BRCA1/2-mutated pancreatic cancer.
Vincent Chung, MD, disucsses results from the phase 2 SWOG S2001 trial which demonstrated that olaparib plus pembrolizumab improved response and progression-free survival in germline BRCA1/2-mutated pancreatic cancer.
Vincent Chung, MD, disucsses...
06/12/2026
Oncology
Alicia Morgans, MD
Videos
Enzalutamide Associated with Increased Cognitive Decline in in Advanced Prostate Cancer
06/12/2026
Alicia Morgans, MD, discusses results from the ARACOG trial which demonstrated that greater enzalutamide was associated with greater cognitive decline compared with darolutamide in patients with advanced prostate cancer.
Alicia Morgans, MD, discusses results from the ARACOG trial which demonstrated that greater enzalutamide was associated with greater cognitive decline compared with darolutamide in patients with advanced prostate cancer.
Alicia Morgans, MD, discusses...
06/12/2026
Oncology
Janice Mehnert, MD
Videos
Adjuvant Pembrolizumab Reduces Distant Recurrence Risk in Merkel Cell Carcinoma
06/12/2026
Janice Mehnert, MD
Janice Mehnert, MD, discusses updated phase 3 STAMP trial results showing that adjuvant pembrolizumab improved distant metastasis-free survival in patients with surgically treated Merkel cell carcinoma, while exploratory analyses suggested...
Janice Mehnert, MD, discusses updated phase 3 STAMP trial results showing that adjuvant pembrolizumab improved distant metastasis-free survival in patients with surgically treated Merkel cell carcinoma, while exploratory analyses suggested...
Janice Mehnert, MD, discusses...
06/12/2026
Oncology
Oleg Gluz, MD
Videos
Longer Docetaxel-Based Chemotherapy Associated With Improved Outcomes in High-Risk HR-Positive, HER2-Negative Breast Cancer
06/11/2026
Oleg Gluz, MD
Oleg Gluz, MD, discusses pooled analyses from the PlanB and ADAPT trials suggesting that longer docetaxel-based chemotherapy may improve outcomes in patients with high-risk HR-positive, HER2-negative early breast cancer.
Oleg Gluz, MD, discusses pooled analyses from the PlanB and ADAPT trials suggesting that longer docetaxel-based chemotherapy may improve outcomes in patients with high-risk HR-positive, HER2-negative early breast cancer.
Oleg Gluz, MD, discusses pooled...
06/11/2026
Oncology
Thumbnail
Videos
How to Implement Subcutaneous Immuno-Oncology for Providers
06/11/2026
Roxana Dronca, MD; Samantha Guild, JD; Jennifer Hunze, MSN, RN; Lucia Nolan, PharmD
Experts discuss practical considerations for implementing subcutaneous immunotherapy in melanoma care, including workflow integration, operational planning, and patient access.
Experts discuss practical considerations for implementing subcutaneous immunotherapy in melanoma care, including workflow integration, operational planning, and patient access.
Experts discuss practical...
06/11/2026
Oncology
Thumbnail
Videos
Advantages of Subcutaneous Immuno-Oncology for Patients
06/11/2026
Roxana Dronca, MD; Samantha Guild, JD; Jennifer Hunze, MSN, RN; Lucia Nolan, PharmD
Experts discuss the patient-centered advantages of subcutaneous immunotherapy for melanoma, including reduced treatment time and greater flexibility in care delivery.
Experts discuss the patient-centered advantages of subcutaneous immunotherapy for melanoma, including reduced treatment time and greater flexibility in care delivery.
Experts discuss the...
06/11/2026
Oncology
Thumbnail
Videos
Subcutaneous Immuno-Oncology Options Available for Metastatic Melanoma
06/11/2026
Roxana Dronca, MD; Samantha Guild, JD; Jennifer Hunze, MSN, RN; Lucia Nolan, PharmD
Experts review the evidence supporting subcutaneous immunotherapy options for melanoma and discuss how pharmacokinetic, efficacy, and safety data inform their use in clinical practice.
Experts review the evidence supporting subcutaneous immunotherapy options for melanoma and discuss how pharmacokinetic, efficacy, and safety data inform their use in clinical practice.
Experts review the evidence...
06/11/2026
Oncology
Thumbnail
Videos
Standard Immuno-Oncology Options for the Melanoma Landscape and Unmet Needs for Patients
06/11/2026
Roxana Dronca, MD; Samantha Guild, JD; Jennifer Hunze, MSN, RN; Lucia Nolan, PharmD
Experts review the evolving immuno-oncology landscape in melanoma and discuss considerations that influence treatment selection beyond efficacy alone.
Experts review the evolving immuno-oncology landscape in melanoma and discuss considerations that influence treatment selection beyond efficacy alone.
Experts review the evolving...
06/11/2026
Oncology
Jamie Chaft, MD
Videos
Adjuvant Nivolumab Fails to Improve DFS Regardless of PD-L1 Status in Non-Small Cell Lung Cancer
06/10/2026
Jamie Chaft, MD
Jamie Chaft, MD, discusses results from the phase 3 EA5142 trial, part of the National Cancer Institute’s ALCHEMIST program, evaluating adjuvant nivolumab in patients with resected EGFR or ALK-negative NSCLC following standard therapy.
Jamie Chaft, MD, discusses results from the phase 3 EA5142 trial, part of the National Cancer Institute’s ALCHEMIST program, evaluating adjuvant nivolumab in patients with resected EGFR or ALK-negative NSCLC following standard therapy.
Jamie Chaft, MD, discusses...
06/10/2026
Oncology

News

Conference Coverage
Olaparib Plus Abiraterone and Prednisone Improved Progression-Free Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations
01/25/2024
Allison Casey
According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...
According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...
According to a phase 2 trial,...
01/25/2024
Oncology
News
Novel Genomic Instability Scar Test for Detecting Homologous Repair Deficiency, Predicting Olaparib Sensitivity Among Patients With Ovarian Cancer
10/16/2023
Allison Casey
The novel, academic-developed Genomic Instability Scar test was determined to reliably detect HRD and predict olaparib sensitivity among patients with ovarian cancer, according to a study.
The novel, academic-developed Genomic Instability Scar test was determined to reliably detect HRD and predict olaparib sensitivity among patients with ovarian cancer, according to a study.
The novel, academic-developed...
10/16/2023
Oncology
News
PARP Inhibitor Plus Androgen Receptor Signaling Inhibitor Combinations for Metastatic Castration-Resistant Prostate Cancer
09/26/2023
Allison Casey
A quantitative synthesis and meta-analysis confirmed the efficacy and safety of PARP inhibitor plus androgen receptor signaling inhibitor combinations for the treatment of patients with metastatic castration-resistant prostate cancer.
A quantitative synthesis and meta-analysis confirmed the efficacy and safety of PARP inhibitor plus androgen receptor signaling inhibitor combinations for the treatment of patients with metastatic castration-resistant prostate cancer.
A quantitative synthesis and...
09/26/2023
Oncology
News
Niraparib Plus Abiraterone Acetate and Prednisone Continues to Benefit Patients with HRR-Altered Metastatic Castration-Resistant Prostate Cancer
09/14/2023
Allison Casey
In the second interim analysis of the phase 3 MAGNITUDE trial, niraparib plus abiraterone acetate and prednisone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer and HRR...
In the second interim analysis of the phase 3 MAGNITUDE trial, niraparib plus abiraterone acetate and prednisone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer and HRR...
In the second interim analysis...
09/14/2023
Oncology
News
Maintenance Niraparib Extended PFS Among Patients With Advanced Ovarian Cancer
07/26/2023
Stephanie Holland
According to results from the phase 3 PRIME study, first-line, maintenance niraparib prolonged PFS with an individualized starting dose that was both safe and effective among patients with newly diagnosed, advanced ovarian cancer.
According to results from the phase 3 PRIME study, first-line, maintenance niraparib prolonged PFS with an individualized starting dose that was both safe and effective among patients with newly diagnosed, advanced ovarian cancer.
According to results from the...
07/26/2023
Oncology
News
Talazoparib With Enzalutamide Approved for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
06/21/2023
On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.
On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.
On June 20, 2023, the US FDA...
06/21/2023
Oncology
News
FDA Approves Olaparib for HRR Gene-Mutated mCRPC
05/20/2020
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib...
05/20/2020
Oncology
News
Total Marrow and Lymphoid Irradiation Shows Promise Prior to alloHCT in Relapsed or Refractory Acute Leukemia
06/15/2026
Emily Estrada
Total marrow and lymphoid irradiation combined with high-dose etoposide and cyclophosphamide was feasible and associated with encouraging outcomes in patients with relapsed or refractory acute leukemia undergoing alloHCT, as demonstrated by...
Total marrow and lymphoid irradiation combined with high-dose etoposide and cyclophosphamide was feasible and associated with encouraging outcomes in patients with relapsed or refractory acute leukemia undergoing alloHCT, as demonstrated by...
Total marrow and lymphoid...
06/15/2026
Oncology
FDA Approval
FDA Approves Capivasertib Plus Abiraterone for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer
06/12/2026
Stephanie Holland
Based on results from the phase 3 CAPItello-281 trial, the FDA has approved capivasertib plus abiraterone and prednisone for adult patients with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that is...
Based on results from the phase 3 CAPItello-281 trial, the FDA has approved capivasertib plus abiraterone and prednisone for adult patients with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that is...
Based on results from the phase...
06/12/2026
Oncology
FDA Approval
FDA Approves Belzutifan Plus Pembrolizumab for Patients With Clear Cell Renal Cell Carcinoma
06/12/2026
Stephanie Holland
Based on results from the phase 3 LITESPARK-022 trial, the FDA has approved adjuvant belzutifan plus pembrolizumab for adult patients with clear cell renal cell carcinoma at intermediate- or high risk of recurrence.
Based on results from the phase 3 LITESPARK-022 trial, the FDA has approved adjuvant belzutifan plus pembrolizumab for adult patients with clear cell renal cell carcinoma at intermediate- or high risk of recurrence.
Based on results from the phase...
06/12/2026
Oncology
News
BAFF-R CAR T Therapy May Overcome Antigen Escape in Relapsed B-Cell Lymphoma
06/11/2026
Stephanie Holland
Results from a phase 1 study demonstrated that PMB-CT01 shows encouraging activity in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Results from a phase 1 study demonstrated that PMB-CT01 shows encouraging activity in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Results from a phase 1 study...
06/11/2026
Oncology
FDA Approval
FDA Approves an Orally Disintegrating Nilotinib Formulation for Patients With Ph-Positive Chronic Myeloid Leukemia
06/11/2026
Stephanie Holland
The FDA has approved an orally disintegrating nilotinib formulation for adults with Ph–positive chronic myeloid leukemia that can be administered with acid-reducing agents and without food restrictions.
The FDA has approved an orally disintegrating nilotinib formulation for adults with Ph–positive chronic myeloid leukemia that can be administered with acid-reducing agents and without food restrictions.
The FDA has approved an orally...
06/11/2026
Oncology
News
KEYNOTE-D46/EVOKE-03 Discontinued After Missing Progression-Free Survival End Point
06/11/2026
Stephanie Holland
Merck and Gilead have discontinued the phase 3 KEYNOTE-D46/EVOKE-03 trial after sacituzumab govitecan plus pembrolizumab failed to achieve a statistically significant PFS benefit in previously untreated metastatic NSCLC.
Merck and Gilead have discontinued the phase 3 KEYNOTE-D46/EVOKE-03 trial after sacituzumab govitecan plus pembrolizumab failed to achieve a statistically significant PFS benefit in previously untreated metastatic NSCLC.
Merck and Gilead have...
06/11/2026
Oncology
News
Bexobrutideg Continues to Demonstrate Clinical Promise Following BTK Inhibitor Resistance in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
06/11/2026
Stephanie Holland
Updated results from a phase 1a/1b study show that bexobrutideg continues to demonstrate strong clinical promise in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Updated results from a phase 1a/1b study show that bexobrutideg continues to demonstrate strong clinical promise in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Updated results from a phase...
06/11/2026
Oncology
News
Addition of Polatuzumab to R-ICE Falls Short in Second-Line Large B-Cell Lymphoma
06/11/2026
Stephanie Holland
Results from a phase 3 study demonstrated that the addition of polatuzumab vedotin to R-ICE did not improve outcomes in relapsed or refractory large B-cell lymphoma.
Results from a phase 3 study demonstrated that the addition of polatuzumab vedotin to R-ICE did not improve outcomes in relapsed or refractory large B-cell lymphoma.
Results from a phase 3 study...
06/11/2026
Oncology
News
Dual-Target CAR T Therapy OL-101 Shows Deep Responses in Heavily Pretreated Patients With Relapsed or Relapsed Multiple Myeloma
06/11/2026
Stephanie Holland
Results from an ongoing phase 1 study demonstrated that OL-101 shows strong clinical promise in heavily pretreated relapsed or refractory multiple myeloma.
Results from an ongoing phase 1 study demonstrated that OL-101 shows strong clinical promise in heavily pretreated relapsed or refractory multiple myeloma.
Results from an ongoing phase 1...
06/11/2026
Oncology
News
KITE-222 Shows Manageable Safety but Limited Activity in Relapsed or Refractory Acute Myeloid Leukemia
06/10/2026
Stephanie Holland
Results from a phase 1 dose-escalation trial demonstrated that KITE-222 demonstrated limited clinical efficacy but tolerable safety in relapsed or refractory acute myeloid leukemia.
Results from a phase 1 dose-escalation trial demonstrated that KITE-222 demonstrated limited clinical efficacy but tolerable safety in relapsed or refractory acute myeloid leukemia.
Results from a phase 1...
06/10/2026
Oncology

Quizzes

Quiz
Pivekimab Sunirine for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasms
06/09/2026
Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?
Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?
Which finding from the CADENZA...
06/09/2026
Oncology
Quiz
Durvalumab Plus BCG for BCG-Naïve Patients With Non-Muscle Invasive Bladder Cancer
06/08/2026
Which key finding from the phase 3 POTOMAC trial led to the FDA approval of durvalumab plus BCG for BCG-naïve patients with high-risk non–muscle-invasive bladder cancer?
Which key finding from the phase 3 POTOMAC trial led to the FDA approval of durvalumab plus BCG for BCG-naïve patients with high-risk non–muscle-invasive bladder cancer?
Which key finding from the phase...
06/08/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 4
05/21/2026
Lucia Masarova, MD
Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.
Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.
Test your understanding of the...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 3
05/21/2026
Lucia Masarova, MD
Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.
Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.
Learn how persistent...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 2
05/21/2026
Lucia Masarova, MD
Review evidence evaluating the association between elevated white blood cell count and thrombotic risk in polycythemia vera.
Review evidence evaluating the association between elevated white blood cell count and thrombotic risk in polycythemia vera.
Review evidence evaluating the...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 1
05/21/2026
Lucia Masarova, MD
Test your knowledge of the clinical relevance of white blood cell count control in polycythemia vera management.
Test your knowledge of the clinical relevance of white blood cell count control in polycythemia vera management.
Test your knowledge of the...
05/21/2026
Oncology
Current First-Line Treatments and Low-Risk Treatment Guidelines in Polycythemia Vera (PV): A Quiz Journey
PV Guidelines Question 5
05/21/2026
Michael R. Grunwald, MD
Learn more about the safety profile of interferon therapy in low-risk polycythemia vera.
Learn more about the safety profile of interferon therapy in low-risk polycythemia vera.
Learn more about the safety...
05/21/2026
Oncology
Current First-Line Treatments and Low-Risk Treatment Guidelines in Polycythemia Vera (PV): A Quiz Journey
PV Guidelines Question 4
05/21/2026
Michael R. Grunwald, MD
Review clinical features that may support consideration of cytoreductive therapy in patients with low-risk polycythemia vera.
Review clinical features that may support consideration of cytoreductive therapy in patients with low-risk polycythemia vera.
Review clinical features that...
05/21/2026
Oncology
Current First-Line Treatments and Low-Risk Treatment Guidelines in Polycythemia Vera (PV): A Quiz Journey
PV Guidelines Question 3
05/21/2026
Michael R. Grunwald, MD
Test your understanding of first-line cytoreductive therapy options for patients with high-risk polycythemia vera.
Test your understanding of first-line cytoreductive therapy options for patients with high-risk polycythemia vera.
Test your understanding of...
05/21/2026
Oncology
Current First-Line Treatments and Low-Risk Treatment Guidelines in Polycythemia Vera (PV): A Quiz Journey
PV Guidelines Question 2
05/20/2026
Learn when cytoreductive therapy should be considered for patients with low-risk polycythemia vera despite treatment with phlebotomy and aspirin.
Learn when cytoreductive therapy should be considered for patients with low-risk polycythemia vera despite treatment with phlebotomy and aspirin.
Learn when cytoreductive therapy...
05/20/2026
Oncology
OLN

HRR

ALIASES

Human recombination repair

References

Homologous recombination repair (HHR) is a DNA repair mechanism that removes damaged DNA by acting on double-strand breaks, interstrand crosslinks, and other kinds of DNA damage.1 DNA damage is repaired with high fidelity by correcting damage with information copied from a homologous undamaged molecule.2 Defects in HRR are present in some cancers.3

Recent News

Conference Coverage
Olaparib Plus Abiraterone and Prednisone Improved Progression-Free Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations
01/25/2024
Allison Casey
According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...
According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...
According to a phase 2 trial,...
01/25/2024
Oncology
News
Novel Genomic Instability Scar Test for Detecting Homologous Repair Deficiency, Predicting Olaparib Sensitivity Among Patients With Ovarian Cancer
10/16/2023
Allison Casey
The novel, academic-developed Genomic Instability Scar test was determined to reliably detect HRD and predict olaparib sensitivity among patients with ovarian cancer, according to a study.
The novel, academic-developed Genomic Instability Scar test was determined to reliably detect HRD and predict olaparib sensitivity among patients with ovarian cancer, according to a study.
The novel, academic-developed...
10/16/2023
Oncology
News
PARP Inhibitor Plus Androgen Receptor Signaling Inhibitor Combinations for Metastatic Castration-Resistant Prostate Cancer
09/26/2023
Allison Casey
A quantitative synthesis and meta-analysis confirmed the efficacy and safety of PARP inhibitor plus androgen receptor signaling inhibitor combinations for the treatment of patients with metastatic castration-resistant prostate cancer.
A quantitative synthesis and meta-analysis confirmed the efficacy and safety of PARP inhibitor plus androgen receptor signaling inhibitor combinations for the treatment of patients with metastatic castration-resistant prostate cancer.
A quantitative synthesis and...
09/26/2023
Oncology
News
Niraparib Plus Abiraterone Acetate and Prednisone Continues to Benefit Patients with HRR-Altered Metastatic Castration-Resistant Prostate Cancer
09/14/2023
Allison Casey
In the second interim analysis of the phase 3 MAGNITUDE trial, niraparib plus abiraterone acetate and prednisone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer and HRR...
In the second interim analysis of the phase 3 MAGNITUDE trial, niraparib plus abiraterone acetate and prednisone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer and HRR...
In the second interim analysis...
09/14/2023
Oncology
News
Maintenance Niraparib Extended PFS Among Patients With Advanced Ovarian Cancer
07/26/2023
Stephanie Holland
According to results from the phase 3 PRIME study, first-line, maintenance niraparib prolonged PFS with an individualized starting dose that was both safe and effective among patients with newly diagnosed, advanced ovarian cancer.
According to results from the phase 3 PRIME study, first-line, maintenance niraparib prolonged PFS with an individualized starting dose that was both safe and effective among patients with newly diagnosed, advanced ovarian cancer.
According to results from the...
07/26/2023
Oncology
News
Talazoparib With Enzalutamide Approved for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
06/21/2023
On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.
On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.
On June 20, 2023, the US FDA...
06/21/2023
Oncology
News
FDA Approves Olaparib for HRR Gene-Mutated mCRPC
05/20/2020
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib...
05/20/2020
Oncology
News
Total Marrow and Lymphoid Irradiation Shows Promise Prior to alloHCT in Relapsed or Refractory Acute Leukemia
06/15/2026
Emily Estrada
Total marrow and lymphoid irradiation combined with high-dose etoposide and cyclophosphamide was feasible and associated with encouraging outcomes in patients with relapsed or refractory acute leukemia undergoing alloHCT, as demonstrated by...
Total marrow and lymphoid irradiation combined with high-dose etoposide and cyclophosphamide was feasible and associated with encouraging outcomes in patients with relapsed or refractory acute leukemia undergoing alloHCT, as demonstrated by...
Total marrow and lymphoid...
06/15/2026
Oncology
FDA Approval
FDA Approves Capivasertib Plus Abiraterone for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer
06/12/2026
Stephanie Holland
Based on results from the phase 3 CAPItello-281 trial, the FDA has approved capivasertib plus abiraterone and prednisone for adult patients with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that is...
Based on results from the phase 3 CAPItello-281 trial, the FDA has approved capivasertib plus abiraterone and prednisone for adult patients with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that is...
Based on results from the phase...
06/12/2026
Oncology
FDA Approval
FDA Approves Belzutifan Plus Pembrolizumab for Patients With Clear Cell Renal Cell Carcinoma
06/12/2026
Stephanie Holland
Based on results from the phase 3 LITESPARK-022 trial, the FDA has approved adjuvant belzutifan plus pembrolizumab for adult patients with clear cell renal cell carcinoma at intermediate- or high risk of recurrence.
Based on results from the phase 3 LITESPARK-022 trial, the FDA has approved adjuvant belzutifan plus pembrolizumab for adult patients with clear cell renal cell carcinoma at intermediate- or high risk of recurrence.
Based on results from the phase...
06/12/2026
Oncology
News
BAFF-R CAR T Therapy May Overcome Antigen Escape in Relapsed B-Cell Lymphoma
06/11/2026
Stephanie Holland
Results from a phase 1 study demonstrated that PMB-CT01 shows encouraging activity in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Results from a phase 1 study demonstrated that PMB-CT01 shows encouraging activity in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Results from a phase 1 study...
06/11/2026
Oncology
FDA Approval
FDA Approves an Orally Disintegrating Nilotinib Formulation for Patients With Ph-Positive Chronic Myeloid Leukemia
06/11/2026
Stephanie Holland
The FDA has approved an orally disintegrating nilotinib formulation for adults with Ph–positive chronic myeloid leukemia that can be administered with acid-reducing agents and without food restrictions.
The FDA has approved an orally disintegrating nilotinib formulation for adults with Ph–positive chronic myeloid leukemia that can be administered with acid-reducing agents and without food restrictions.
The FDA has approved an orally...
06/11/2026
Oncology
News
KEYNOTE-D46/EVOKE-03 Discontinued After Missing Progression-Free Survival End Point
06/11/2026
Stephanie Holland
Merck and Gilead have discontinued the phase 3 KEYNOTE-D46/EVOKE-03 trial after sacituzumab govitecan plus pembrolizumab failed to achieve a statistically significant PFS benefit in previously untreated metastatic NSCLC.
Merck and Gilead have discontinued the phase 3 KEYNOTE-D46/EVOKE-03 trial after sacituzumab govitecan plus pembrolizumab failed to achieve a statistically significant PFS benefit in previously untreated metastatic NSCLC.
Merck and Gilead have...
06/11/2026
Oncology
News
Bexobrutideg Continues to Demonstrate Clinical Promise Following BTK Inhibitor Resistance in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
06/11/2026
Stephanie Holland
Updated results from a phase 1a/1b study show that bexobrutideg continues to demonstrate strong clinical promise in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Updated results from a phase 1a/1b study show that bexobrutideg continues to demonstrate strong clinical promise in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Updated results from a phase...
06/11/2026
Oncology
News
Addition of Polatuzumab to R-ICE Falls Short in Second-Line Large B-Cell Lymphoma
06/11/2026
Stephanie Holland
Results from a phase 3 study demonstrated that the addition of polatuzumab vedotin to R-ICE did not improve outcomes in relapsed or refractory large B-cell lymphoma.
Results from a phase 3 study demonstrated that the addition of polatuzumab vedotin to R-ICE did not improve outcomes in relapsed or refractory large B-cell lymphoma.
Results from a phase 3 study...
06/11/2026
Oncology
News
Dual-Target CAR T Therapy OL-101 Shows Deep Responses in Heavily Pretreated Patients With Relapsed or Relapsed Multiple Myeloma
06/11/2026
Stephanie Holland
Results from an ongoing phase 1 study demonstrated that OL-101 shows strong clinical promise in heavily pretreated relapsed or refractory multiple myeloma.
Results from an ongoing phase 1 study demonstrated that OL-101 shows strong clinical promise in heavily pretreated relapsed or refractory multiple myeloma.
Results from an ongoing phase 1...
06/11/2026
Oncology
News
KITE-222 Shows Manageable Safety but Limited Activity in Relapsed or Refractory Acute Myeloid Leukemia
06/10/2026
Stephanie Holland
Results from a phase 1 dose-escalation trial demonstrated that KITE-222 demonstrated limited clinical efficacy but tolerable safety in relapsed or refractory acute myeloid leukemia.
Results from a phase 1 dose-escalation trial demonstrated that KITE-222 demonstrated limited clinical efficacy but tolerable safety in relapsed or refractory acute myeloid leukemia.
Results from a phase 1...
06/10/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use